Appellate Hearing In Similac Claim Case Set For Nov. 9
This article was originally published in The Tan Sheet
Executive Summary
Arguments on appeal will be heard Nov. 9 in the Seventh Circuit federal court case Mead Johnson v. Abbott Labs. The case concerns the "1st Choice of Doctors" claim for Abbott's Similac infant formula.
You may also be interested in...
Abbott "1st Choice Of Doctors" Infant Formula Claim "Misleading" - Judge
Abbott Labs is temporarily barred from using the claim "1st choice of doctors" on advertising or labeling for its Similac or other infant brands except for Isomil in a preliminary injunction handed down March 18 by Evansville, Ind. federal court Judge David Hamilton. Mead Johnson (Enfamil) requested the injunction in a suit filed in July ("The Tan Sheet" July 27, 1998, p. 1).
Abbott Ensure vitamin content comparison to multivitamins unfounded -- FTC.
ABBOTT AGREES TO HALT ENSURE UNSUBSTANTIATED "DOCTOR RECOMMENDED" CLAIMS under a proposed settlement with the Federal Trade Commission. The agreement would prohibit the Abbott Park, Ill.-based OTC and nutritional product marketer from claiming in future ads that Ensure is recommended by doctors as a meal replacement and/or supplement for healthy adults without appropriate substantiation, FTC announced Jan. 2. Comments on the proposed settlement will be accepted through March 2.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC